Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways

Breast Cancer Research

Volumn 16, Issue 2, 2014, Pages

  Singel, Stina M ^a,b   Batten, Kimberly ^a   Cornelius, Crystal ^a   Jia, Gaoxiang ^a   Fasciani, Gail ^a   Barron, Summer L ^a   Wright, Woodring E ^a   Shay, Jerry W ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIGEL; MESSENGER RNA; PROGESTERONE RECEPTOR; PROTEIN KINASE; RECEPTOR INTERACTING PROTEIN KINASE 2; SHORT HAIRPIN RNA; STRESS ACTIVATED PROTEIN KINASE; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE 2; RIPK2 PROTEIN, HUMAN; TAXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL MIGRATION ASSAY; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MOUSE; NONHUMAN; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SURVIVAL TIME; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; TUMOR XENOGRAFT; WESTERN BLOTTING; WOUND HEALING; CELL MOTION; DRUG EFFECTS; DRUG SCREENING; FEMALE; FLUORESCENCE MICROSCOPY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; PROGNOSIS; SECONDARY; TUMOR CELL LINE; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MCF-7 CELLS; MICROSCOPY, FLUORESCENCE; NEOPLASM INVASIVENESS; NF-KAPPA B; PROGNOSIS; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASE 2; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TAXOIDS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901314474     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3629     Document Type: Article

References (44)

1. Lupfer C, Thomas PG, Anand PK, Vogel P, Milasta S, Martinez J, Huang G, Green M, Kundu M, Chi H, Xavier RJ, Green DR, Lamkanfi M, Dinarello CA, Doherty PC, Kanneganti TD. Receptor interacting protein kinase 2-mediated mitophagy regulates inflammasome activation during virus infection. Nat Immunol 2013, 14:480-488. 10.1038/ni.2563, 3631456, 23525089.
2. Magalhaes JG, Lee J, Geddes K, Rubino S, Philpott DJ, Girardin SE. Essential role of Rip2 in the modulation of innate and adaptive immunity triggered by Nod1 and Nod2 ligands. Eur J Immunol 2011, 41:1445-1455. 10.1002/eji.201040827, 21469090.
3. Tigno-Aranjuez JT, Asara JM, Abbott DW. Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses. Genes Dev 2010, 24:2666-2677. 10.1101/gad.1964410, 2994040, 21123652.
4. Inohara N, del Peso L, Koseki T, Chen S, Nunez G. RICK, a novel protein kinase containing a caspase recruitment domain, interacts with CLARP and regulates CD95-mediated apoptosis. J Biol Chem 1998, 273:12296-12300. 10.1074/jbc.273.20.12296, 9575181.
5. McCarthy JV, Ni J, Dixit VM. RIP2 is a novel NF-kappaB-activating and cell death-inducing kinase. J Biol Chem 1998, 273:16968-16975. 10.1074/jbc.273.27.16968, 9642260.
6. Thome M, Hofmann K, Burns K, Martinon F, Bodmer JL, Mattmann C, Tschopp J. Identification of CARDIAK, a RIP-like kinase that associates with caspase-1. Curr Biol 1998, 8:885-888. 10.1016/S0960-9822(07)00352-1, 9705938.
7. Singel SM, Cornelius C, Batten K, Fasciani G, Wright WE, Lum L, Shay JW. A Targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer. Clin Cancer Res 2013, 19:2061-2070. 10.1158/1078-0432.CCR-13-0082, 23479679.
8. Navas TA, Baldwin DT, Stewart TA. RIP2 is a Raf1-activated mitogen-activated protein kinase kinase. J Biol Chem 1999, 274:33684-33690. 10.1074/jbc.274.47.33684, 10559258.
9. Jacquet S, Nishino Y, Kumphune S, Sicard P, Clark JE, Kobayashi KS, Flavell RA, Eickhoff J, Cotten M, Marber MS. The role of RIP2 in p38 MAPK activation in the stressed heart. J Biol Chem 2008, 283:11964-11971. 10.1074/jbc.M707750200, 3774113, 18310079.
10. Helbig G, Christopherson KW, Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller KD, Broxmeyer HE, Nakshatri H. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003, 278:21631-21638. 10.1074/jbc.M300609200, 12690099.
11. Kang H, Lee M, Choi KC, Shin DM, Ko J, Jang SW. N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell invasion through suppressing NF-KB activation and inhibiting matrix metalloproteinase-9 expression. J Cell Biochem 2012, 113:2845-2855. 10.1002/jcb.24159, 22488409.
12. Moreau M, Mourah S, Dosquet C. beta-Catenin and NF-kappaB cooperate to regulate the uPA/uPAR system in cancer cells. Int J Cancer 2011, 128:1280-1292. 10.1002/ijc.25455, 20473943.
13. Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinthu N, Zhang Y, Mazumdar A, Hilsenbeck SG, Mills GB, Brown PH. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res 2013, 73:3470-3480. 10.1158/0008-5472.CAN-12-4524-T, 23633491.
14. Huang C, Rajfur Z, Borchers C, Schaller MD, Jacobson K. JNK phosphorylates paxillin and regulates cell migration. Nature 2003, 424:219-223. 10.1038/nature01745, 12853963.
15. Lee MH, Koria P, Qu J, Andreadis ST. JNK phosphorylates beta-catenin and regulates adherens junctions. FASEB J 2009, 23:3874-3883. 10.1096/fj.08-117804, 2774999, 19667122.
16. Kawahara E, Maenaka S, Shimada E, Nishimura Y, Sakurai H. Dynamic regulation of extracellular signal-regulated kinase (ERK) by protein phosphatase 2A regulatory subunit B56gamma1 in nuclei induces cell migration. PLoS One 2013, 8:e63729. 10.1371/journal.pone.0063729, 3660565, 23704935.
17. Moore HM, Gonzalez ME, Toy KA, Cimino-Mathews A, Argani P, Kleer CG. EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis. Breast Cancer Res Treat 2013, 138:741-752. 10.1007/s10549-013-2498-x, 3690767, 23539298.
18. The Cancer Genome Atlas Data Portal. https://tcga-data.nci.nih.gov/tcga/.
19. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005, 102:13550-13555. 10.1073/pnas.0506230102, 1197273, 16141321.
20. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, Klijn JG, Larsimont D, Buyse M, Bontempi G, Delorenzi M, Piccart MJ, Sotiriou C. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007, 25:1239-1246. 10.1200/JCO.2006.07.1522, 17401012.
21. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009. 10.1056/NEJMoa021967, 12490681.
22. Gene Expression Omnibus (GEO) public functional genomics data repository. http://www.ncbi.nlm.nih.gov/geo/.
23. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, Liu ET, Miller L, Nordgren H, Ploner A, Sandelin K, Shaw PM, Smeds J, Skoog L, Wedren S, Bergh J. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 2005, 7:R953-R964. 10.1186/bcr1325, 1410752, 16280042.
24. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL, Klijn JG, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007, 13:3207-3214. 10.1158/1078-0432.CCR-06-2765, 17545524.
25. Computational Cancer Biologty, Division of Molecular Carcinogenesis, Netherlands Cancer Institute Data portal. http://bioinformatics.nki.nl/data.php.
26. A subtyping tool for triple-negative breast cancer. https://cbc.mc.vanderbilt.edu/tnbc/.
27. Abbott DW, Wilkins A, Asara JM, Cantley LC. The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr Biol 2004, 14:2217-2227. 10.1016/j.cub.2004.12.032, 15620648.
28. Gruneberg U, Neef R, Li X, Chan EH, Chalamalasetty RB, Nigg EA, Barr FA. KIF14 and citron kinase act together to promote efficient cytokinesis. J Cell Biol 2006, 172:363-372. 10.1083/jcb.200511061, 2063646, 16431929.
29. Ewing RM, Chu P, Elisma F, Li H, Taylor P, Climie S, McBroom-Cerajewski L, Robinson MD, O'Connor L, Li M, Taylor R, Dharsee M, Ho Y, Heilbut A, Moore L, Zhang S, Ornatsky O, Bukhman YV, Ethier M, Sheng Y, Vasilescu J, Abu-Farha M, Lambert JP, Duewel HS, Stewart II, Kuehl B, Hogyue K, Colwill K, Gladwish K, Muskat B. Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol Syst Biol 2007, 3:89. 1847948, 17353931.
30. Network CGA. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. 10.1038/nature11412, 3465532, 23000897.
31. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011, 121:2750-2767. 10.1172/JCI45014, 3127435, 21633166.
32. Zhang D, Lin J, Han J. Receptor-interacting protein (RIP) kinase family. Cell Mol Immunol 2010, 7:243-249. 10.1038/cmi.2010.10, 20383176.
33. Ko BS, Chang TC, Chen CH, Liu CC, Kuo CC, Hsu C, Shen YC, Shen TL, Golubovskaya VM, Chang CC, Shyue SK, Liou JY. Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B. Life Sci 2010, 86:199-206. 10.1016/j.lfs.2009.12.003, 20006625.
34. Golubovskaya VM, Cance W. Focal adhesion kinase and p53 signal transduction pathways in cancer. Front Biosci 2010, 15:901-912.
35. Windheim M, Lang C, Peggie M, Plater LA, Cohen P. Molecular mechanisms involved in the regulation of cytokine production by muramyl dipeptide. Biochem J 2007, 404:179-190. 10.1042/BJ20061704, 1868792, 17348859.
36. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA, Connelly PA. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem 1996, 271:695-701. 10.1074/jbc.271.2.695, 8557675.
37. Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol 1999, 17:2334-2340.
38. van der Heiden-van der Loo M, Schaapveld M, Ho VK, Siesling S, Rutgers EJ, Peeters PH. Outcomes of a population-based series of early breast cancer patients with micrometastases and isolated tumour cells in axillary lymph nodes. Ann Oncol 2013, 24:2794-2801. 10.1093/annonc/mdt243, 23864096.
39. Chang MC, Escallon JM, Colgan TJ. Prognostic significance of a positive axillary lymph node fine-needle aspirate in patients with invasive breast carcinoma. Cancer cytopathology 2013, 122:138-144.
40. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434. 10.1158/1078-0432.CCR-06-3045, 17671126.
41. O'Shaughnessy J, Schwartzberg L, Danso M, Rugo H, Miller K, Yardley D, Carlson R, Finn R, Charpentier E, Freese M, Gupta S, Blackwood-Chirchir A, Winer EP. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011, 29. suppl; abstr 1007.
42. Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili-Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 2013, 14:933-942. 10.1016/S1470-2045(13)70335-8, 23932548.
43. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009, 9:537-549. 10.1038/nrc2694, 19629069.
44. Conde C, Rambout X, Lebrun M, Lecat A, Di Valentin E, Dequiedt F, Piette J, Gloire G, Legrand S. The inositol phosphatase SHIP-1 inhibits NOD2-induced NF-kappaB activation by disturbing the interaction of XIAP with RIP2. PLoS One 2012, 7:e41005. 10.1371/journal.pone.0041005, 3398883, 22815893.